Testosterone Deficiency and Risk Factors in the Metabolic Syndrome: Implications for Erectile Dysfunction (Q37881318)

24 August 2017

1 reference

title

Testosterone deficiency and risk factors in the metabolic syndrome: implications for erectile dysfunction (English)

1 reference

24 August 2017

Testosterone Deficiency and Risk Factors in the Metabolic Syndrome: Implications for Erectile Dysfunction (English)

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

3 December 2024

1 reference

1 reference

1 reference

Abdulmaged Traish

2

1 reference

24 August 2017

Andre T. Guay

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC:MED AND EXT_ID:21621084

3 December 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=21621084

3 December 2024

publication date

3 April 2011

1 reference

full work available at URL

24 August 2017

https://api.elsevier.com/content/article/PII:S0094014311000188?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

https://api.elsevier.com/content/article/PII:S0094014311000188?httpAccept=text/plain

3 December 2024

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Urologic Clinics of North America

3 December 2024

published in

1 reference

24 August 2017

volume

38

1 reference

24 August 2017

issue

2

1 reference

24 August 2017

page(s)

175-183

1 reference

Endogenous sex hormones and metabolic syndrome in aging men.

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Evolving issues in male hypogonadism: evaluation, management, and related comorbidities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Contribution of age and declining androgen levels to features of the metabolic syndrome in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Androgen inactivation and steroid-converting enzyme expression in abdominal adipose tissue in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Sex hormones, inflammation and the metabolic syndrome: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Aging, androgens, and the metabolic syndrome in a longitudinal study of aging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Relative androgen deficiency in relation to obesity and metabolic status in older men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Facing the diabetes epidemic--mandatory reporting of glycosylated hemoglobin values in New York City

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Increasing Trends in Incidence of Overweight and Obesity over 5 Decades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Prevalence of the metabolic syndrome among U.S. adolescents using the definition from the International Diabetes Federation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Low testosterone levels are common and associated with insulin resistance in men with diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Low serum testosterone concentration in middle-aged men with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: The Telecom Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Increasing insulin resistance is associated with a decrease in Leydig cell testosterone secretion in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Association of endogenous testosterone with blood pressure and left ventricular mass in men. The Tromsø Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Waist circumference and testosterone levels in community dwelling men. The Tromsø study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Androgen treatment of abdominally obese men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Androgen receptor gene CAG repeat length and body mass index modulate the safety of long-term intramuscular testosterone undecanoate therapy in hypogonadal men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Androgen supplementation in eugonadal men with osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

The decline of androgen levels in elderly men and its clinical and therapeutic implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

New perspectives on Mars and Venus: unravelling the role of androgens in gender differences in cardiovascular biology and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Androgen deficiency, diabetes, and the metabolic syndrome in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Androgen deficiency as a predictor of metabolic syndrome in aging men: an opportunity for intervention?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Androgens and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Lower endogenous androgen levels and dyslipidemia in men with non-insulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Beneficial effects of testosterone undecanoate on the lipoprotein profiles in healthy elderly men. A placebo controlled study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Androgen deficiency and atherosclerosis: The lipid link

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Association between lipid profile and circulating concentrations of estrogens in young men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Low serum testosterone and high serum estradiol associate with lower extremity peripheral arterial disease in elderly men. The MrOS Study in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Psychobiologic correlates of the metabolic syndrome and associated sexual dysfunction.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Measures of adiposity in the identification of metabolic abnormalities in elderly men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Effects of acute hyperinsulinemia on testosterone serum concentrations in adult obese and normal-weight men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Leptin and androgens in male obesity: evidence for leptin contribution to reduced androgen levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

A 5-year follow-up study of disease incidence in men with an abnormal hormone pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

High proportions of erectile dysfunction in men with the metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Prevalence of erectile dysfunction in patients with metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Sex steroids and endothelial function: translating basic science to clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Physiological testosterone replacement and arterial endothelial function in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Low testosterone level is an independent determinant of endothelial dysfunction in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Endogenous hormones and carotid atherosclerosis in elderly men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

The inverse relationship between thoracic aortic intima media thickness and testosterone level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Changes in aortic endothelium ultrastructure in male rats following castration, replacement with testosterone and administration of 5alpha-reductase inhibitor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Increased carotid atherosclerosis in andropausal middle-aged men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Testosterone as a protective factor against atherosclerosis--immunomodulation and influence upon plaque development and stability

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Efficacy and safety of two different testosterone undecanoate formulations in hypogonadal men with metabolic syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Sex hormones and hemostatic risk factors for coronary heart disease in men with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

inferred from DOI database lookup

7 January 2021

based on heuristic

Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts Male Aging Study

3

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

3 December 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

The dark side of testosterone deficiency: I. Metabolic syndrome and erectile dysfunction

3 December 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

The Dark Side of Testosterone Deficiency: II. Type 2 Diabetes and Insulin Resistance

3 December 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Is the metabolic syndrome an independent risk factor for erectile dysfunction?

3 December 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Androgen deficiency and abnormal penile duplex parameters in obese men with erectile dysfunction

3 December 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidence

3 December 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

HYPOGONADISM AND METABOLIC SYNDROME: IMPLICATIONS FOR TESTOSTERONE THERAPY

3 December 2024

77

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study

3 December 2024

80

1 reference

https://api.crossref.org/works/10.1016/J.UCL.2011.02.004

3 December 2024

Identifiers

1 reference

24 August 2017

1 reference